补肺活血汤对稳定期慢性阻塞性肺疾病患者临床疗效及安全性的影响

Clinical safety and efficacy of the Bufei Huoxue decoction on chronic obstructive pulmonary disease at stable stage

目的:研究分析补肺活血汤治疗稳定期慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Disease,COPD)的治疗效果。方法:选取2017年5月-2018年6月本院收治的稳定期COPD患者50例,采用数字编号后随机分为两组,各25例,对照组采用常规西药,观察组在对照组基础上给予补肺活血汤治疗,记录并对比两组数据的肺功能指标和临床疗效指标。结果:治疗前两组稳定期COPD患者间的第一秒钟用力呼气量(Forced Expiratory Volume in 1 second,FEV1)、用力肺活量(Forced Vital Capacity,FVC)、FVC/FEV1指标相比较(P>0.05)。治疗后,两组稳定期COPD患者FEV1、FVC均高于治疗前,且观察组FVC[(2.55±0.41)L]和FEV1[(3.74±0.34)L]明显高于对照组(P<0.05);观察组稳定期COPD患者治疗总有效率(96.00%)明显高于对照组的72.00%(P<0.05);两组间不良反应情况比较差异无统计学意义(P>0.05)。结论:补肺活血汤治疗稳定期慢性阻塞性肺疾病具有显著的疗效,能够有效缓解患者临床症状及体征,改善肺功能,值得推广。

Objective: To study the efficacy of the Bufei Huoxue decoction (补肺活血汤) on COPD at stable stage. Methods: 50 patients with COPD at stable stage were randomly divided into two groups, 25 in each group. The control group was treated with conventional western medicine. The observation group was treated with the Bufei Huoxue decoction more. Results: There was no significant difference in lung function between two groups before treatment (P>0.05). The FEV1 and FVC in the two groups after treatment were higher, and the FVC and FEV1 in the observation group were significantly higher than the control group (P<0.05). The total efficiency in the observation group was 96.00%, which was significantly higher than 72.00% in the control group (P<0.05). There was no significant difference in adverse reactions between two groups (P>0.05). Conclusion: The Bufei Huoxue decoction is effective on patients with COPD at stable stage, can effectively alleviate the clinical symptoms and signs and improve lung function, is worth promoting.